Klinikum Osnabrück GmbH

At Klinikum Osnabrück GmbH, research in Nervous System Diseases focuses on difficult-to-control seizure disorders, including refractory focal onset epilepsy, focal epilepsy, primary generalized tonic-clonic seizures, and status epilepticus in older adults. These studies are designed to assess new treatment options and improve seizure control, safety, and overall effectiveness of care.

• Testing new therapies for refractory status epilepticus and established status epilepticus
• Evaluating seizure reduction in focal onset seizures and primary generalized tonic-clonic seizures
• Assessing safety and tolerability of emerging anti-seizure treatments

These trials aim to expand options for patients whose epilepsy remains uncontrolled with standard treatment, while also generating evidence for better symptom management in clinical practice.

The site also conducts clinical research in Neoplasms, especially multiple myeloma and chronic lymphocytic leukemia. The main goal is to improve cancer treatment outcomes by comparing combination strategies, strengthening response rates, and exploring approaches that may delay disease progression.

• Studying treatment effectiveness in multiple myeloma and high-risk multiple myeloma
• Evaluating maintenance and induction strategies to improve minimal residual disease outcomes
• Investigating new options for previously untreated chronic lymphocytic leukemia

These oncology trials reflect a strong interest in refining therapy for blood cancers and identifying regimens that may offer deeper and more durable responses.

Within Hemic and Lymphatic Diseases, the research portfolio centers on multiple myeloma and chronic lymphocytic leukemia. The studies are aimed at testing newer treatment combinations, improving response quality, and examining whether patients can achieve better long-term disease control.

• Comparing treatment combinations in newly diagnosed multiple myeloma
• Assessing MRD negativity as a marker of deeper treatment response
• Exploring new therapeutic strategies for treatment-naive chronic lymphocytic leukemia

At Medizinische Klinik III, these hematology trials support efforts to optimize care for patients with complex blood cancers and to improve outcomes beyond standard treatment approaches.

Another important area of research addresses treatment-related complications in cancer care, particularly chemotherapy-induced polyneuropathy. The studies aim to reduce nerve damage and improve quality of life for people receiving chemotherapy.

• Preventing chemotherapy-induced polyneuropathy during cancer treatment
• Reducing the severity of nerve-related symptoms linked to chemotherapy
• Improving patient comfort and daily functioning during oncology care

This work adds a supportive-care dimension to the site’s oncology research, with a practical focus on making cancer treatment more tolerable for patients.